Jennifer Hyer1, Claire Ulrickson1, Elise Yerelian2, Torri D Metz3, Amanda A Allshouse3, M Camille Hoffman4,5. 1. Department of Obstetrics and Gynecology, Denver Health and Hospital Authority, Denver, Colorado. 2. Department of Family Medicine, SCL Health, Denver, Colorado. 3. Department of Obstetrics and Gynecology, University of Utah Health Sciences Center, Salt Lake City, Utah. 4. Department of Obstetrics and Gynecology, University of Colorado, Denver, Colorado. 5. Department of Psychiatry, University of Colorado, Denver, Colorado.
Abstract
BACKGROUND: Substance use disorders often coexist with depression. The objective of this study was to establish whether pregnant women who report depressive symptomatology were more likely to report use of alcohol, tobacco, and marijuana during pregnancy. STUDY DESIGN: This was a secondary analysis of prospectively collected data from the Maternal-Fetal Medicine Units Network Preterm Prediction Study. Self-reported history of alcohol, tobacco, and marijuana use was compared between pregnant women with and without depressive symptomatology with adjustment for demographic factors. RESULTS: After adjustment for demographic factors, women with depressive symptomatology were more likely to report: any alcohol use (odds ratio [OR]: 1.4, 95% confidence interval [CI]: 1.1-1.8), > 1 drink per week (OR: 1.3, 95% CI: 1.0-1.8), and >1 drink per day (OR: 2.2, 95% CI: 1.5-3.4). Women with depressive symptomatology were also more likely to report use of marijuana (OR: 1.8, 95% CI: 1.2-2.6) and cigarettes (OR: 1.4, 95% CI: 1.1-1.7). CONCLUSION: Depressive symptomatology was associated with an increase in self-reported the use of alcohol, tobacco, and marijuana during pregnancy. These data reveal the importance of targeted screening of pregnant women with depressive symptomatology for substance use. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
BACKGROUND: Substance use disorders often coexist with depression. The objective of this study was to establish whether pregnant women who report depressive symptomatology were more likely to report use of alcohol, tobacco, and marijuana during pregnancy. STUDY DESIGN: This was a secondary analysis of prospectively collected data from the Maternal-Fetal Medicine Units Network Preterm Prediction Study. Self-reported history of alcohol, tobacco, and marijuana use was compared between pregnant women with and without depressive symptomatology with adjustment for demographic factors. RESULTS: After adjustment for demographic factors, women with depressive symptomatology were more likely to report: any alcohol use (odds ratio [OR]: 1.4, 95% confidence interval [CI]: 1.1-1.8), > 1 drink per week (OR: 1.3, 95% CI: 1.0-1.8), and >1 drink per day (OR: 2.2, 95% CI: 1.5-3.4). Women with depressive symptomatology were also more likely to report use of marijuana (OR: 1.8, 95% CI: 1.2-2.6) and cigarettes (OR: 1.4, 95% CI: 1.1-1.7). CONCLUSION:Depressive symptomatology was associated with an increase in self-reported the use of alcohol, tobacco, and marijuana during pregnancy. These data reveal the importance of targeted screening of pregnant women with depressive symptomatology for substance use. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Authors: Mariah Jorda; Bradley J Conant; Anne Sandstrom; Marilyn G Klug; Jyoti Angal; Larry Burd Journal: PLoS One Date: 2021-02-11 Impact factor: 3.240
Authors: Lynn M Yee; Deborah Kacanek; Chase Brightwell; Lisa B Haddad; Jennifer Jao; Kathleen M Powis; Tzy-Jyun Yao; Emily Barr; Carly Broadwell; Suzanne Siminski; George R Seage; Ellen G Chadwick Journal: JAMA Netw Open Date: 2021-12-01